Logo-bi
Original Article

1. PCL-based nanoparticles for doxorubicin-ezetimibe co-delivery: A combination therapy for prostate cancer using a drug repurposing strategy
Mina Yousefnezhad, Soodabeh Davaran* ORCID, Mirzaagha Babazadeh, Abolfazl Akbarzadeh, Hamidreza Pazoki-Toroudi
Bioimpacts. 2023;13(3): 241-253. doi: 10.34172/bi.2023.24252
PMCID: PMC10329752     PMID: 37431480     Scopus ID: 85157052599    
Article
PDF
Full Text
XML
Cited By:
10
0
4
Drug repurposing is an effective strategy for identifying and using approved drugs for new therapeutic purposes. We investigated co-delivery of the antitumor drugs, doxorubicin (DOX), and ezetimibe (EZ) as a cholesterol uptake-blocking drug with PCEC on prostate cancer cell line (PC3).
Original Article

2. Evaluation of specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer
Gelareh Vahabzadeh ORCID, Amirreza Pashapour-Yeganeh, Maryam Eini, Morad Roudbaraki, Ebrahim Esmati, Amirhoushang Poorkhani, Solmaz Khalighfard, Ali Mohammad Alizadeh* ORCID
Bioimpacts. 2025;15: 30510 | Published on: 2025 Jan 26. doi: 10.34172/bi.30510
Article
PDF
Suppl 1
Suppl 2
Suppl 3
XML
Cited By:
0
0
0
Original Article

3. Chrysosplenetin B suppresses the growth of human prostate cancer cells by inducing G1 cell cycle arrest
Gang He* ORCID, Yanjiao Feng, Tangcong Chen, Yiyuan Zhang, Li Liang, Jun Yan, Yanxia Song, Fengzheng Chen, Wei Liu* ORCID
Bioimpacts. 2025;15: 30688 | Published on: 2025 Mar 02. doi: 10.34172/bi.30688
Article
PDF
Suppl 1
XML
Cited By:
0
0
0

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate (2024): 20% 
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded; Google Scholar;   SJR; Essential Science Indicators; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO
Member of COPE
Follower of ICMJE
Permission: Creative Commons